Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 472

The DOI matches its Crossref record; 152 of the 152 references it cites were found in a registry or an index.

DNA Methylation Cancer Biomarkers: Translation to the Clinic

Open access
Locke, Warwick J., Guanzon, Dominic, Ma, Chenkai, Liew, Yi Jin, Duesing, Konsta R., Fung, Kim Y.C., Ross, Jason P.·2019·Frontiers in Genetics

Abstract

Carcinogenesis is accompanied by widespread DNA methylation changes within the cell. These changes are characterised by a globally hypomethylated genome with focal hypermethylation of numerous 5'-cytosine-phosphate-guanine-3' (CpG) islands, often spanning gene promoters and first exons. Many of these epigenetic changes occur early in tumorigenesis and are highly pervasive across a tumour type. This allows DNA methylation cancer biomarkers to be suitable for early detection and also to have utility across a range of areas relevant to cancer detection and treatment. Such tests are also simple in construction, as only one or a few loci need to be targeted for good test coverage. These properties make cancer-associated DNA methylation changes very attractive for development of cancer biomarker tests with substantive clinical utility. Across the patient journey from initial detection, to treatment and then monitoring, there are several points where DNA methylation assays can inform clinical practice. Assays on surgically removed tumour tissue are useful to determine indicators of treatment resistance, prognostication of outcome or to molecularly characterise, classify and determine the tissue of origin of a tumour. Cancer-associated DNA methylation changes can also be detected with accuracy in the cell-free DNA present in blood, stool, urine and other biosamples. Such tests hold great promise for the development of simple, economical and highly specific cancer detection tests suitable for population-wide screening, with several successfully translated examples already. The ability of circulating tumour DNA liquid biopsy assays to monitor cancer in situ also allows for the ability to monitor response to therapy, to detect minimal residual disease and as an early biomarker for cancer recurrence. This review will summarise existing DNA methylation cancer biomarkers used in clinical practice across the application domains above, discuss what makes a suitable DNA methylation cancer biomarker and identify barriers to translation. We discuss technical factors such as the analytical performance and product-market fit, factors that contribute to successful downstream investment, including geography, and how this impacts intellectual property (IP), regulatory hurdles and the future of the marketplace and healthcare system.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fgene.2019.01150

Cites

152 of 152 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 152 references

Cited by

See all 472

Metadata

Authors
Locke, W. J., Guanzon, D., Ma, C., Liew, Y. J., Duesing, K. R., Fung, K. Y. C., & Ross, J. P.
Venue
Frontiers in Genetics
Published
2019-11-14
Volume
10
Pages
1150-1150
ISSN
1664-8021 (ISSN-L)
OpenAlex
W2984827653
Cited by
472
References
152
FWCI
15.76
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: DNA Methylation Cancer Biomarkers: Translation to the Clinic. https://app.cochat.ai/papers/10.3389/fgene.2019.01150
The paper
Locke, W. J., Guanzon, D., Ma, C., Liew, Y. J., Duesing, K. R., Fung, K. Y. C., & Ross, J. P. (2019). DNA Methylation Cancer Biomarkers: Translation to the Clinic. Frontiers in Genetics. https://doi.org/10.3389/fgene.2019.01150

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.